Literature DB >> 7872636

[Use of myoplasty after acute mediastinitis occurring after heart surgery. Apropos of 167 cases].

C Guedon1, I Gandjbackch, A Piwnica, M Romano, B Andreassian.   

Abstract

Infected median sternotomy often requires open wound management. A large thoracic defect usually results in subsequent exposure of heart, great vessels, aorto-coronary bypass grafting or vascular prosthesis. After thorough wound debridement, coverage with muscle transposition was carried out in a series of 167 cases observed over a period of 10 years. Transposition of both pectoralis major muscles on internal pedicles was performed in 75 cases. In 27 of these cases, internal mammary grafting did not preclude their use. Since 1986, intrathoracic transposition of the trapezius muscle has been our treatment of choice in 25 cases, most frequently combined with a double pectoralis major transposition. Rectus abdomini muscle flap was seldom used alone whereas latissimus dorsi was mainly used as a salvage flap. Muscle transposition provided effective heart and great vessel protection after acute hemorrhage in 18 cases. This series confirms that mortality and mean hospital stay have decreased dramatically since the routine use of muscle transposition.

Entities:  

Mesh:

Year:  1994        PMID: 7872636

Source DB:  PubMed          Journal:  Ann Chir Plast Esthet        ISSN: 0294-1260            Impact factor:   0.660


  2 in total

1.  The alternative supply of the pectoralis major flap based medially in cases with previous surgical use of the internal thoracic artery: an anatomical study.

Authors:  M Marín-Guzke; A Sánchez-Olaso; F J Fernández-Camacho
Journal:  Surg Radiol Anat       Date:  2005-11-09       Impact factor: 1.246

2.  Chronic encapsulated mediastinal abscess presenting with remote cutaneous fistulization 12 years after redo aortic valve replacement for prosthetic valve endocarditis.

Authors:  Pankaj Kaul; Syed S A Qadri; Mohd Riaz
Journal:  J Cardiothorac Surg       Date:  2006-08-24       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.